In this case, the binding of dimethylpyrano and prenyl groups on cycle A (AIF, derrone) would enhance cytotoxic activity, rather than on cycle B (neobavaoflavone, sigmoidin H), which would nevertheless provide an advantage against EGFR-mutated GBM. This evidence concerns the gene EGFR and glioblastoma.